Results 51 to 60 of about 2,551 (122)

Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1004-1015, October 2026.
A sex‐stratified genome‐wide association study of sulfonylurea response identified sex‐specific genetic loci associated with HbA1c reduction in individuals with type 2 diabetes. Replication and functional validation supported a male‐specific association at the TMEM64/NECAB1 locus, highlighting the potential of sex‐informed pharmacogenomics to advance ...
Joseph H. Breeyear, John S. House, Mark Kvale, Stella Nam, Farida S. Akhtari, Hetal S. Shah, Monique M. Hedderson, Kathleen M. Giacomini, Josyf C. Mychaleckyj, Alessandro Doria, Michael J. Wagner, Josephine H. Li, Sook Wah Yee, John B. Buse, Richard P. Woychik, Daniel M. Rotroff, Alison A. Motsinger‐Reif   +16 more
wiley   +1 more source

Effect of glimepiride on paraoxonase activity

, 2006
In this study, the effect of glimepiride on serum paraoxonase activity (EC 3.1.8.1.) has been investigated in vitro . The inhibition and activation effects of this drug on serum paraoxonase activity was measured spectrophotometrically using paraoxon as ...
Demir, Y, Demir, N, Nadaroglu, Hayrunnisa   +2 more
core   +1 more source

Development and Characterization of Glimepiride Novel Solid Nanodispersion for Improving Its Oral Bioavailability

Scientia Pharmaceutica, 2020
Glimepiride is an antidiabetic drug which is one of the third generation sulfonylureas. It belongs to class II, according to the BCS (Biopharmaceutical Classification System), which is characterized by low solubility and high permeability.
Mona Qushawy, Ali Nasr, Shady Swidan, Yasmin Mortagi   +3 more
doaj   +1 more source

Mechanism‐Informed Pharmacotherapy Optimization and Deprescribing: A Redox–Mitochondrial Framework

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
From cumulative drug burden to mitochondrial stress and functional decline. The graphical abstract summarizes the central concept of the review, illustrating how cumulative pharmacotherapy exposure may contribute to redox–mitochondrial stress and thereby reduce biological and functional resilience.
Boštjan Martinc
wiley   +1 more source

Glimepiride-pioglitazone hydrochloride in the treatment of type 2 diabetes

, 2009
The purpose of this article is to review the effectiveness and tolerability of pioglitazone and glimepiride combination treatment for type 2 diabetes, particularly in the context of metabolic control and cardiovascular prevention. We reviewed studies of
Sibilla Anna Teresa Salvadeo, Salvadeo SAT, Giuseppe Derosa, DEROSA, GIUSEPPE   +3 more
core   +1 more source

EFFECTS OF METFORMIN PLUS GLICLAZIDE VERSUS METFORMIN PLUS GLIMEPIRIDE ON CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS [PDF]

Al-Azhar Journal of Pharmaceutical Sciences, 2014
High plasma glucose level, lipid profile disturbances and high plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes.
Gamil Abd-Allah
doaj   +1 more source

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9336-9345, October 2026.
ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea, Hyesung Lee, Young Min Cho, You‐Jung Choi, Ju‐Young Shin, Katsiaryna Bykov   +5 more
wiley   +1 more source

Glimepiride protects cortical neurones against PrP82–146.

, 2013
(A) The survival of cortical neurones pre-treated for 1 hour with control medium (•) or with 5 µM glimepiride (○) and incubated with varying concentrations of PrP82–146 for 5 days. Values shown are the mean average neuronal survival ± SD, n = 12. (B) The
Luisa Diomede (108301), Alun Williams (41959), Clive Bate (41957), Mourad Tayebi (41958), Mario Salmona (108340)   +4 more
core   +1 more source

Nanomedicine for the Treatment of Pediatric Type 2 Diabetes: Progress, Challenges, and Translational Perspectives

Advanced Therapeutics, Volume 9, Issue 9, September 2026.
Overview of pharmaceutical nanocarriers in diabetes, illustrating applications of nanotechnology including enhanced drug and targeted drug delivery and nanosensors for glucose monitoring and diagnosis. ABSTRACT Pediatric type 2 diabetes mellitus (T2DM) is rapidly emerging as a critical global health concern, driven largely by rising childhood obesity ...
Nnamdi Ikemefuna Okafor, Bukosi Baloyi, Yahya E. Choonara   +2 more
wiley   +1 more source

UV VIS method of estimation for Glimepiride in Tablets

, 2023
<p><strong><span><span>Abstract </span></span></strong></p> <p><span>A simple spectrophotometric method was developed and validated for determination of Glimepiride in pharmaceutical products ...
Minela Dacić, Mirsad Džambić, Larisa Alagić-Džambić, Mergime Gjuraj, Minela Hukić   +4 more
core   +1 more source